SCHEMBL2368328

SCHEMBL2368328

Nc1nc(NCc2ccccn2)c2c(-c3ccccc3)c(CC3CC3)sc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 8/20 0.44
KCNH2 Q12809 8/20 0.43
TNF P01375 1/20 0.43
MAPK1 P28482 1/20 0.43
NOD1 Q9Y239 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
JAK2 O60674 2/20 0.40
CDK2 P24941 2/20 0.40
TYK2 P29597 2/20 0.40
GSK3B P49841 2/20 0.40
JAK3 P52333 2/20 0.40
BTK Q06187 2/20 0.40
AURKB Q96GD4 2/20 0.40
IRAK4 Q9NWZ3 2/20 0.40
IGF1R P08069 1/20 0.40
PIM1 P11309 1/20 0.40
SRC P12931 1/20 0.40
CSNK2A2 P19784 1/20 0.40
JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385252 0.82 KCNH2 (0.43) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL3385287 0.82 PRKCI (0.51) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL3382742 0.75 TNF (0.70) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL2369220 0.73 MEN1 (0.52) KCNH2MEN1KMT2AADORA2AADORA1
SCHEMBL3382594 0.69 KCNH2 (0.49) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL12188788 0.69 KCNH2 (0.78) KCNA5KCNH2JAK2CDK2TYK2
SCHEMBL2368795 0.68 TNF (0.59) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL3387426 0.67 ADORA2A (0.57) TNFMAPK1NOD1ADORA2AADORA1
SCHEMBL2368922 0.67 KCNH2 (0.48) KCNA5KCNH2TNFMAPK1NOD1
SCHEMBL2368953 0.66 KCNH2 (0.48) KCNA5KCNH2TNFMAPK1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 KCNA5 8/4885KCNH2 6/4885TNF 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.